

Biopharmaceuticals

Advancing treatment options for patients

Teva is investing in biopharmaceutical research and development to bring more treatment options to patients, supporting our mission to improve the lives of patients.

What are biopharmaceuticals?

Complex medicines produced by living cells or organisms



Often produced using cutting-edge biotechnological methods



Tend to be heat sensitive, easy to contaminate



Difficult and expensive to make, store and transport



Potential for precise, targeted treatments



Usually injected into the body


How complex are they?

Small molecule drug
(e.g. aspirin)




0.18 kD
(21 Atoms)

Small biologic
(e.g. somatropin)



~22 kD
(~3,000 Atoms)

Large biologic
(e.g. monoclonal antibody)



~150 kD
(>20,000 Atoms)

Complexity

Two classes of biopharmaceuticals

Innovator biologics

An innovator biologic is the original version of a biopharmaceutical treatment. It is approved based on, among other things, a full complement of safety and effectiveness data.

Biosimilars

A biosimilar is a biopharmaceutical that is highly similar to a specific innovator biologic. It has no clinically meaningful differences in terms of safety, purity and potency.

Biologics in numbers

1982
insulin becomes the first biologic cleared for human use

59%
of all biologic sales are in the US – the world's biggest market

26%
a quarter of US national prescription spending goes to biologics, but only 2% of patients use them

Biosimilars in numbers

2006
the first biosimilar is approved in Europe (a human growth hormone)

30%
average price difference between a biosimilar and a biologic

87%
of all biosimilars are sold in Europe

Concept to clinic

Teva is dedicating global facilities to the discovery, development, clinical and non-clinical research and production of innovative biologics and biosimilars.

Biopharma at Teva

Teva is investing in biopharmaceuticals as part of our growth plan for the future and to help patients around the world. Biopharmaceuticals combine our strength in generics with our knowledge of complex medicine.

tevaparm.com